Gilead Sciences (GILD) News Today $92.58 +0.17 (+0.18%) (As of 11/29/2024 05:27 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Erste Asset Management GmbH Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)Erste Asset Management GmbH bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 409,829 shares of the biopharmaceutical company's stock, valDecember 1 at 7:44 AM | marketbeat.comTrue Wealth Design LLC Sells 11,635 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)True Wealth Design LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 94.8% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 635 shares of the biopharmaceutical company's stock after selling 11,635 shares duringDecember 1 at 7:36 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Bellevue Group AGBellevue Group AG raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,027 shares of the biopharmaceutical company's stocDecember 1 at 7:13 AM | marketbeat.comBRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Decreases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 13.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 207,875 shares of the biopharmaceuticalDecember 1 at 6:32 AM | marketbeat.comPDT Partners LLC Makes New $1.77 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD)PDT Partners LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 21,107 shares of the biopharmaceutical company's stock, valDecember 1 at 5:46 AM | marketbeat.comMerdad Parsey Sells 164,211 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) StockGilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Merdad Parsey sold 164,211 shares of the company's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.November 29 at 10:11 PM | marketbeat.comGilead Sciences chief medical officer sells $15m in stockNovember 29 at 8:19 PM | investing.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Captrust Financial AdvisorsCaptrust Financial Advisors increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,680,699 shares of the biopharmaceutical companNovember 29 at 8:31 AM | marketbeat.comVestal Point Capital LP Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)Vestal Point Capital LP acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 200,000 shares of the biopharmaceutical cNovember 29 at 8:19 AM | marketbeat.comMartingale Asset Management L P Sells 48,012 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Martingale Asset Management L P lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 15.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 255,510 shares of the biophNovember 29 at 7:24 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Healthcare of Ontario Pension Plan Trust FundHealthcare of Ontario Pension Plan Trust Fund grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 118.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 249,370 shares of the biopharmaNovember 29 at 5:41 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,628,942 shares of the biopharmaceuticaNovember 28 at 9:10 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Zurcher Kantonalbank Zurich CantonalbankZurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 9.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 848,235 shares of the bioNovember 28 at 8:21 AM | marketbeat.comJeffrey Bluestone Sells 6,788 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) StockNovember 28 at 8:13 AM | insidertrades.comAcuta Capital Partners LLC Acquires New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)Acuta Capital Partners LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 19,500 shares of the biopharmaceutical company's stock, valued at approximately $1,63November 28 at 8:12 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by CreativeOne Wealth LLCCreativeOne Wealth LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 41.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,135 shares of the biopharmaceutical cNovember 28 at 7:16 AM | marketbeat.comGlenmede Trust Co. NA Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Glenmede Trust Co. NA lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 292,048 shares of the biopharmaceutical company's stock after sNovember 28 at 6:49 AM | marketbeat.comBridgewater Associates LP Sells 583,702 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Bridgewater Associates LP cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 73.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 206,942 shares of the biopharmaceutical compNovember 28 at 6:49 AM | marketbeat.comGilead announces PURPOSE 2 trial data published in NEJMNovember 28 at 6:27 AM | markets.businessinsider.comRBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)November 28 at 6:27 AM | markets.businessinsider.comTownsquare Capital LLC Has $11.32 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Townsquare Capital LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 14.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,964 shares of the biopharmaceutical companyNovember 28 at 6:23 AM | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by D.A. Davidson & CO.D.A. Davidson & CO. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,517 shares of the biopharmaceutical company's stoNovember 28 at 5:47 AM | marketbeat.comGilead Sciences Inc (GILD) Announces Promising Results from Phase 3 HIV Prevention TrialNovember 27, 2024 | gurufocus.comGilead Announces New England Journal of Medicine Publication of PURPOSE 2 ResultsNovember 27, 2024 | businesswire.comKiltearn Partners LLP Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)Kiltearn Partners LLP bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 72,600 shares of the biopharmaceuticNovember 27, 2024 | marketbeat.comGilead Sciences Q3 Earnings TranscriptNovember 27, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Massachusetts Financial Services Co. MAMassachusetts Financial Services Co. MA decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,407 shares of the biopharmaceNovember 27, 2024 | marketbeat.comContrasting Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD)November 27, 2024 | americanbankingnews.comFY2024 EPS Estimates for Gilead Sciences Lifted by AnalystNovember 27, 2024 | americanbankingnews.comPrincipal Street Partners LLC Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Principal Street Partners LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 22.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 75,992 shares of the biopharmaceutical company's stock after selling 21,930 shares duringNovember 26, 2024 | marketbeat.comFmr LLC Raises Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)Fmr LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 79.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,162,319 shares of the biopharmaceutical company's sNovember 26, 2024 | marketbeat.comDai ichi Life Insurance Company Ltd Sells 205,601 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)Dai ichi Life Insurance Company Ltd lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 54.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 171,416 shares of the biopharmaceutical company's stockNovember 26, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Sells 260,875 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)The Manufacturers Life Insurance Company decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 6,342,411 shares of the biopharmaceutical company's stock after selling 260November 26, 2024 | marketbeat.comHancock Whitney Corp Has $4.21 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Hancock Whitney Corp increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 12.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,172 shares of the biopharmaceutical company's stock afterNovember 25, 2024 | marketbeat.comHarvest Fund Management Co. Ltd Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Harvest Fund Management Co. Ltd grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 26.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,377 shares of the biopharmaceutical company'sNovember 25, 2024 | marketbeat.comCerity Partners LLC Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Cerity Partners LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 253,872 shares of the biopharmaceutical company's stock aftNovember 25, 2024 | marketbeat.comGilead Sciences (NASDAQ:GILD) Price Target Raised to $96.00November 25, 2024 | americanbankingnews.comConnor Clark & Lunn Investment Management Ltd. Reduces Stake in Gilead Sciences, Inc. (NASDAQ:GILD)Connor Clark & Lunn Investment Management Ltd. reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 95.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,514 shares of the biopharNovember 25, 2024 | marketbeat.comGilead Sciences FY2024 EPS Estimate Lifted by Zacks ResearchGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Zacks Research raised their FY2024 earnings per share estimates for Gilead Sciences in a note issued to investors on Wednesday, November 20th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earningsNovember 25, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Daiwa Securities Group Inc.Daiwa Securities Group Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 41.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 305,083 shares of the biopharmaceutical coNovember 24, 2024 | marketbeat.comLPL Financial LLC Acquires 78,839 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)LPL Financial LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 7.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,137,381 shares of the biopharmaceutical company's stock after purchNovember 24, 2024 | marketbeat.comMeridian Wealth Management LLC Invests $3.56 Million in Gilead Sciences, Inc. (NASDAQ:GILD)Meridian Wealth Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,449 shares of the biopharmaNovember 23, 2024 | marketbeat.comGilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Icon Wealth Advisors LLCIcon Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1,281.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,684 shares of the biopharmaceuticaNovember 23, 2024 | marketbeat.comEagle Asset Management Inc. Has $17.41 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Eagle Asset Management Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 23.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 207,698 shares of the biopharmaceutical company's stock afNovember 23, 2024 | marketbeat.comZacks Research Forecasts Higher Earnings for Gilead SciencesNovember 23, 2024 | americanbankingnews.comGilead price target raised to $96 from $70 at UBSNovember 22, 2024 | markets.businessinsider.comThe Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.November 22, 2024 | businesswire.comQ3 EPS Estimates for Gilead Sciences Increased by AnalystGilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Equities research analysts at Zacks Research raised their Q3 2026 earnings estimates for shares of Gilead Sciences in a report issued on Wednesday, November 20th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company wilNovember 22, 2024 | marketbeat.com8,154 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Altiora Financial Group LLCAltiora Financial Group LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,154 shares of the biopharmaceutical company's stock, valued at approximately $684,000.November 22, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)Charles Schwab Investment Management Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,752,November 22, 2024 | marketbeat.com Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. GILD Media Mentions By Week GILD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GILD News Sentiment▼1.100.87▲Average Medical News Sentiment GILD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GILD Articles This Week▼4619▲GILD Articles Average Week Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AMGN News Today VRTX News Today REGN News Today ALNY News Today BIIB News Today UTHR News Today INCY News Today NBIX News Today BMRN News Today EXEL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GILD) was last updated on 12/1/2024 by MarketBeat.com Staff From Our PartnersThe latest trend in real estateThese vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, t...Pacaso | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBofA is watching for a market topU.S. tech stocks have soared so high for so long that they're no longer just minting new millionaires... Th...Chaikin Analytics | SponsoredPaypal, Tesla, SpaceX… Elon's next project is bigger than them allIn February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored***TODAY ONLY*** Is this Trump’s Favorite Coin?Donald Trump just emphatically became America's first crypto president. Trump plans to make America, "the...Weiss Ratings | SponsoredThis Crisis Could Be Worse Than 2008Underneath the surface, cracks are forming. Cracks that threaten to shatter everything we know. America ...Behind the Markets | SponsoredYou’re invited! See my NEWEST trading strategyThis could easily be the most lucrative new trading strategy of 2025... So you’re not going to want to miss...Monument Traders Alliance | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
